Emergency Use Authorizations (EUAs) Versus FDA Approval: Implications for COVID-19 and Public Health
Diana M. Zuckerman
Abstract
Emergency Use Authorizations (EUAs) Versus FDA Approval: Implications for COVID-19 and Public Health Diana M. Zuckerman PhD Affiliation Diana M. Zuckerman is president of the National Center for Health Research, Washington, DC.CopyRightCorrespondence should be sent to Diana M. Zuckerman, 1001 Connecticut Ave, NW, Suite 1100, Washington, DC 20036 (e-mail: [email protected]). Reprints can be ordered at http://www.ajph.org by clicking the "Reprints" link. https://doi.org/10.2105/AJPH.2021.306273 Accepted: March 07, 2021 Published Online: May 05, 2021
Topics & Concepts
AuthorizationCoronavirus disease 2019 (COVID-19)Public health2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Political scienceSuiteFamily medicineLibrary scienceMedicineLawVirologyComputer securityNursingComputer scienceInfectious disease (medical specialty)DiseasePathologyOutbreakDisaster Response and ManagementPublic Health Policies and EducationHealthcare cost, quality, practices